{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T19:20:11Z","timestamp":1769109611423,"version":"3.49.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T00:00:00Z","timestamp":1637107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s40256-021-00508-3","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T01:02:23Z","timestamp":1637110943000},"page":"263-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["SGLT-2 Inhibitors on Top of Current Pharmacological Treatments for Heart Failure: A Comparative Review on Outcomes and Cost Effectiveness"],"prefix":"10.1007","volume":"22","author":[{"given":"Ilaria","family":"Cavallari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernesto","family":"Maddaloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annunziata","family":"Nusca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dario","family":"Tuccinardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Buzzetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Pozzilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Grigioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"issue":"1","key":"508_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ehf2.12005","volume":"1","author":"P Ponikowski","year":"2014","unstructured":"Ponikowski P, et al. Heart failure: preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4\u201325.","journal-title":"ESC Heart Fail."},{"issue":"11","key":"508_CR2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","volume":"21","author":"NR Jones","year":"2019","unstructured":"Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306\u201325.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"508_CR3","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ejhf.822","volume":"19","author":"MA Mamas","year":"2017","unstructured":"Mamas MA, et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. Eur J Heart Fail. 2017;19(9):1095\u2013104.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"508_CR4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","volume":"113","author":"VL Roger","year":"2013","unstructured":"Roger VL. Epidemiology of heart failure. Circ Res. 2013;113(6):646\u201359.","journal-title":"Circ Res"},{"issue":"36","key":"508_CR5","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"16","key":"508_CR6","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"2","key":"508_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","volume":"6","author":"DK McGuire","year":"2021","unstructured":"McGuire DK, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes. JAMA Cardiol. 2021;6(2):148.","journal-title":"JAMA Cardiol."},{"issue":"10","key":"508_CR8","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1056\/NEJM199209033271003","volume":"327","author":"S Yusuf","year":"1992","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327(10):685\u201391.","journal-title":"N Engl J Med"},{"issue":"4","key":"508_CR9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","volume":"33","author":"DV Exner","year":"1999","unstructured":"Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. J Am Coll Cardiol. 1999;33(4):916\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"508_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJM199209033271001","volume":"327","author":"MA Pfeffer","year":"1992","unstructured":"Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327(10):669\u201377.","journal-title":"N Engl J Med"},{"issue":"16","key":"508_CR11","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.","journal-title":"J Am Coll Cardiol"},{"issue":"27","key":"508_CR12","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129\u20132200m.","journal-title":"Eur Heart J"},{"issue":"9","key":"508_CR13","doi-asserted-by":"publisher","first-page":"e3075","DOI":"10.1210\/clinem\/dgaa427","volume":"105","author":"I Cavallari","year":"2020","unstructured":"Cavallari I, et al. The vicious circle of left ventricular dysfunction and diabetes: from pathophysiology to emerging treatments. J Clin Endocrinol Metab. 2020;105(9):e3075\u201389.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"508_CR14","doi-asserted-by":"publisher","first-page":"e3124","DOI":"10.1002\/dmrr.3124","volume":"35","author":"I Cavallari","year":"2019","unstructured":"Cavallari I, Maddaloni E. Cardiovascular effects of SGLT-2 inhibitors: what we have learned from cardiovascular outcome trials and what we still need to understand. Diabetes Metab Res Rev. 2019;35(4):e3124.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"508_CR15","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","volume":"41","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255\u2013323.","journal-title":"Eur Heart J"},{"issue":"5","key":"508_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325(5):293\u2013302.","journal-title":"N Engl J Med"},{"issue":"23","key":"508_CR17","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"K Swedberg","year":"1987","unstructured":"Swedberg K, Idanpaan-Heikkila U, Remes J. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316(23):1429\u201335.","journal-title":"N Engl J Med"},{"issue":"17","key":"508_CR18","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure. Circulation. 2002;106(17):2194\u20139.","journal-title":"Circulation"},{"issue":"9146","key":"508_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"HJ Dargie","year":"1999","unstructured":"Dargie HJ, Lechat P. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9\u201313.","journal-title":"Lancet"},{"issue":"9169","key":"508_CR20","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"A Hjalmarson","year":"1999","unstructured":"Hjalmarson A, et al. Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001\u20137.","journal-title":"Lancet"},{"issue":"10","key":"508_CR21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341(10):709\u201317.","journal-title":"N Engl J Med"},{"issue":"14","key":"508_CR22","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"508_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"508_CR24","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejheart.2005.03.006","volume":"8","author":"J Abdulla","year":"2006","unstructured":"Abdulla J, et al. Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction\u2013a meta-analysis. Eur J Heart Fail. 2006;8(1):90\u20136.","journal-title":"Eur J Heart Fail"},{"issue":"22","key":"508_CR25","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"508_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00392-012-0467-8","volume":"102","author":"M B\u00f6hm","year":"2013","unstructured":"B\u00f6hm M, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol. 2013;102(1):11\u201322.","journal-title":"Clin Res Cardiol"},{"issue":"11","key":"508_CR27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJVV McMurray","year":"2014","unstructured":"McMurray JJVV, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993\u20131004.","journal-title":"N Engl J Med"},{"issue":"21","key":"508_CR28","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJVV McMurray","year":"2019","unstructured":"McMurray JJVV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"2","key":"508_CR29","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","volume":"141","author":"MN Kosiborod","year":"2020","unstructured":"Kosiborod MN, et al. Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF Trial. Circulation. 2020;141(2):90\u20139.","journal-title":"Circulation"},{"issue":"15","key":"508_CR30","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"10254","key":"508_CR31","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819\u201329.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"508_CR32","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","volume":"143","author":"SD Anker","year":"2021","unstructured":"Anker SD, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status. Circulation. 2021;143(4):337\u201349.","journal-title":"Circulation"},{"issue":"14","key":"508_CR33","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/jama.2020.1906","volume":"323","author":"MC Petrie","year":"2020","unstructured":"Petrie MC, et al. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA. 2020;323(14):1353.","journal-title":"JAMA"},{"issue":"10","key":"508_CR34","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","volume":"8","author":"SD Solomon","year":"2020","unstructured":"Solomon SD, et al. Effect of dapagliflozin in patients with hfref treated with sacubitril\/valsartan. JACC Heart Fail. 2020;8(10):811\u20138.","journal-title":"JACC Heart Fail."},{"issue":"7","key":"508_CR35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/ejhf.1867","volume":"22","author":"P Dewan","year":"2020","unstructured":"Dewan P, et al. Efficacy and safety of sodium\u2013glucose co-transporter inhibition according to left ventricular ejection fraction in DAPA-HF. Eur J Heart Fail. 2020;22(7):1247\u201358.","journal-title":"Eur J Heart Fail"},{"key":"508_CR36","doi-asserted-by":"crossref","unstructured":"EuroQol\u2014a new facility for the measurement of health-related quality of life. Health Policy (New. York). 16(3):199\u2013208 (1990)","DOI":"10.1016\/0168-8510(90)90421-9"},{"issue":"4","key":"508_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s11892-020-1292-5","volume":"20","author":"Y Yoshida","year":"2020","unstructured":"Yoshida Y, Cheng X, Shao H, Fonseca VA, Shi L. A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes. Curr Diab Rep. 2020;20(4):12.","journal-title":"Curr Diab Rep"},{"issue":"7","key":"508_CR38","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s40261-020-00929-z","volume":"40","author":"R Arbel","year":"2020","unstructured":"Arbel R, Aboalhasan E, Hammerman A, Azuri J. Sodium-glucose cotransporter 2 inhibitors for prevention of heart failure events in patients with type 2 diabetes mellitus: a cost per outcome analysis. Clin Drug Investig. 2020;40(7):665\u20139.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"508_CR39","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1093\/oxfordjournals.eurheartj.a015466","volume":"18","author":"JJV McMurray","year":"1997","unstructured":"McMurray JJV, McGuire A, Davie AP, Hughes D. Cost-effectiveness of different ACE inhibitor treatment scenarios post-myocardial infarction. Eur Heart J. 1997;18(9):1411\u20135.","journal-title":"Eur Heart J"},{"issue":"4","key":"508_CR40","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/0735-1097(95)00284-1","volume":"26","author":"J Tsevat","year":"1995","unstructured":"Tsevat J, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995;26(4):914\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"508_CR41","unstructured":"P. Shekelle, et al. Pharmacologic management of heart failure and left ventricular systolic dysfunction: effect in female, black, and diabetic patients, and cost-effectiveness. Evid Rep Technol Assess (Summ). 2003;(82):1\u20136."},{"issue":"21","key":"508_CR42","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1001\/jama.284.21.2748","volume":"284","author":"KA Phillips","year":"2000","unstructured":"Phillips KA. Health and economic benefits of increased \u03b2-blocker use following myocardial infarction. JAMA. 2000;284(21):2748.","journal-title":"JAMA"},{"issue":"11","key":"508_CR43","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ejhf.1978","volume":"22","author":"P McEwan","year":"2020","unstructured":"McEwan P, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020;22(11):2147\u201356.","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"508_CR44","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1177\/2047487320938272","volume":"28","author":"F Savira","year":"2020","unstructured":"Savira F, et al. Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. Eur J Prev Cardiol. 2020;28(9):975\u201382.","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"508_CR45","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1002\/ehf2.12844","volume":"7","author":"Y Yao","year":"2020","unstructured":"Yao Y, Zhang R, An T, Zhao X, Zhang J. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China. ESC Heart Fail. 2020;7(6):3582\u201392.","journal-title":"ESC Heart Fail."},{"issue":"12","key":"508_CR46","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/heartjnl-2016-310661","volume":"104","author":"JJV McMurray","year":"2018","unstructured":"McMurray JJV, et al. Cost-effectiveness of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018;104(12):1006\u201313.","journal-title":"Heart"},{"issue":"10","key":"508_CR47","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s40273-018-0688-4","volume":"36","author":"A Gandjour","year":"2018","unstructured":"Gandjour A, Ostwald DA. Sacubitril\/Valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany. Pharmacoeconomics. 2018;36(10):1285\u201396.","journal-title":"Pharmacoeconomics"},{"key":"508_CR48","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa153","author":"I Cavallari","year":"2020","unstructured":"Cavallari I, Maddaloni E, Grigioni F. Implementing the treatment of heart failure with SGLT-2 inhibitors and sacubitril-valsartan: does money matter? Eur J Prev Cardiol. 2020. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa153.","journal-title":"Eur J Prev Cardiol"},{"key":"508_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaa136","author":"R Arbel","year":"2020","unstructured":"Arbel R, Aboalhasan E, Hammerman A, Azuri J. Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis. Eur. J Prev Cardiol. 2020. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa136.","journal-title":"J Prev Cardiol."},{"issue":"13","key":"508_CR50","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1136\/heartjnl-2013-304598","volume":"100","author":"A Griffiths","year":"2014","unstructured":"Griffiths A, Paracha N, Davies A, Branscombe N, Cowie MR, Sculpher M. The cost effectiveness of ivabradine in the treatment of chronic heart failure from the UK National Health Service perspective. Heart. 2014;100(13):1031\u20136.","journal-title":"Heart"},{"issue":"5","key":"508_CR51","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003221","volume":"5","author":"AR Kansal","year":"2016","unstructured":"Kansal AR, et al. Cost-effectiveness of ivabradine for heart failure in the United States. J Am Heart Assoc. 2016;5(5):e003221. https:\/\/doi.org\/10.1161\/JAHA.116.003221.","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"508_CR52","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S1071-9164(05)80006-5","volume":"1","author":"H Glick","year":"1995","unstructured":"Glick H, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail. 1995;1(5):371\u201380.","journal-title":"J Card Fail"},{"issue":"9","key":"508_CR53","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2165\/00019053-200119090-00002","volume":"19","author":"M Ekman","year":"2001","unstructured":"Ekman M, Zethraeus N, J\u00f6nsson B. Cost effectiveness of bisoprolol in the treatment of chronic congestive heart failure in Sweden: analysis using data from the Cardiac Insufficiency Bisoprolol Study II trial. Pharmacoeconomics. 2001;19(9):901\u201316.","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"508_CR54","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1161\/01.CIR.0000157146.86758.BC","volume":"111","author":"WS Weintraub","year":"2005","unstructured":"Weintraub WS, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005;111(9):1106\u201313.","journal-title":"Circulation"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-021-00508-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-021-00508-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T02:12:33Z","timestamp":1651543953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-021-00508-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,17]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["508"],"URL":"https:\/\/doi.org\/10.1007\/s40256-021-00508-3","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,17]]},"assertion":[{"value":"6 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive any funding for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"IC received honoraria from BMS-Pfizer and Boehringer Ingelheim. EM has received grants from scientific societies supported by Lilly and AstraZeneca and honoraria or consulting fees from Merck-Serono, Pikdare, AstraZeneca, and Abbott. RB has received honoraria or consulting fees from Sanofi, Eli Lilly, Abbott, and AstraZeneca. PP has received research support from Eli Lilly and Company and serves on the speaker bureau for Sanofi\u2010Aventis. AN, DT, and FG have no conflicts of interests related to this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Dr. Cavallari and Prof. Grigioni discussed the content of the article. All authors contributed to the literature search. Drs Cavallari and Maddaloni and Prof. Grigioni drafted the first version of the manuscript. Dr. Cavallari drafted the tables and figures. Drs Nusca and Tuccinardi and Profs Buzzetti and Pozzilli critically revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}